| An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective (NCT02116803) | Novartis Pharmaceuticals | 2014-05-28 |
| Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia. (NCT02049450) | Novartis Pharmaceuticals | 2014-05-28 |
| PD of VAY736 in Patients With Primary Sjögren's Syndrome (NCT02149420) | Novartis Pharmaceuticals | 2014-05-23 |
| Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly (NCT02060383) | Novartis Pharmaceuticals | 2014-05-23 |
| Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer (NCT02088684) | Novartis Pharmaceuticals | 2014-05-19 |
| Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase (NCT02032173) | Novartis Pharmaceuticals | 2014-05-19 |
| Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors (NCT02077933) | Novartis Pharmaceuticals | 2014-05-14 |
| A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer (NCT02058381) | Novartis Pharmaceuticals | 2014-05-06 |
| Study to Evaluate the Impact of the "PROactive Telecoaching Program" on Physical Activity in Patients With COPD. (NCT01992081) | Novartis Pharmaceuticals | 2014-05-01 |
| Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure (NCT01982292) | Novartis Pharmaceuticals | 2014-05-01 |
| Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer (NCT02069093) | Novartis Pharmaceuticals | 2014-05-01 |
| A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL (NCT02081378) | Novartis Pharmaceuticals | 2014-04-24 |
| A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients (NCT02130024) | Novartis Pharmaceuticals | 2014-04-11 |
| 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis (NCT01989468) | Novartis Pharmaceuticals | 2014-04-10 |
| Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab (NCT02559622) | Novartis Pharmaceuticals | 2014-04-01 |
| Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD. (NCT01996319) | Novartis Pharmaceuticals | 2014-04-01 |
| Study of Muscle Effects of BYM338 in Mechanically Ventilated Patients (NCT01868685) | Novartis Pharmaceuticals | 2014-04-01 |
| Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension (NCT01865188) | Novartis Pharmaceuticals | 2014-04-01 |
| Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients. (NCT01837927) | Novartis Pharmaceuticals | 2014-04-01 |
| A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis (NCT02087059) | Novartis Pharmaceuticals | 2014-04-01 |
| Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients (NCT02125734) | Novartis Pharmaceuticals | 2014-04-01 |
| UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD) (NCT01988662) | Novartis Pharmaceuticals | 2014-04-01 |
| REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy (NCT02115113) | Novartis Pharmaceuticals | 2014-03-28 |
| Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201 (NCT02075008) | Novartis Pharmaceuticals | 2014-03-27 |
| Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. (NCT02038036) | Novartis Pharmaceuticals | 2014-03-25 |
| A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) (NCT02078609) | Novartis Pharmaceuticals | 2014-03-20 |
| Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma (NCT02083354) | Novartis Pharmaceuticals | 2014-03-18 |
| Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers (NCT02034110) | Novartis Pharmaceuticals | 2014-03-12 |
| Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF (NCT02007720) | Novartis Pharmaceuticals | 2014-03-12 |
| Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis (NCT02250443) | Novartis Pharmaceuticals | 2014-03-11 |
| Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women (NCT01923168) | Novartis Pharmaceuticals | 2014-03-11 |
| LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib (NCT02040870) | Novartis Pharmaceuticals | 2014-03-07 |
| Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease (NCT01915303) | Novartis Pharmaceuticals | 2014-03-06 |
| A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer (NCT02051751) | Novartis Pharmaceuticals | 2014-03-05 |
| Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye (NCT01986907) | Novartis Pharmaceuticals | 2014-03-04 |
| Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment. (NCT02048787) | Novartis Pharmaceuticals | 2014-03-01 |
| Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme (NCT01934361) | Novartis Pharmaceuticals | 2014-02-28 |
| Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis (NCT02074982) | Novartis Pharmaceuticals | 2014-02-26 |
| Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain (NCT02039947) | Novartis Pharmaceuticals | 2014-02-21 |
| Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen (NCT01985334) | Novartis Pharmaceuticals | 2014-02-14 |
| Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML (NCT01883362) | Novartis Pharmaceuticals | 2014-02-06 |
| Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy (NCT02024932) | Novartis Pharmaceuticals | 2014-02-04 |
| Study of the Vascular Effects of Serelaxin (NCT01979614) | Novartis Pharmaceuticals | 2014-02-03 |
| Study of Efficacy and Safety of CVAA489 in Hypertensive Patients (NCT02062645) | Novartis Pharmaceuticals | 2014-02-01 |
| Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. (NCT01605981) | Novartis Pharmaceuticals | 2014-02-01 |
| LDE225 for Patients With PTCH1 or SMO Mutated Tumors (NCT02002689) | Novartis Pharmaceuticals | 2014-02-01 |
| Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus (NCT02044848) | Novartis Pharmaceuticals | 2014-02-01 |
| Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses (NCT01948817) | Novartis Pharmaceuticals | 2014-02-01 |
| Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects (NCT02074995) | Novartis Pharmaceuticals | 2014-02-01 |
| Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD (NCT01959516) | Novartis Pharmaceuticals | 2014-02-01 |
| Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients (NCT02064868) | Novartis Pharmaceuticals | 2014-01-31 |
| Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome. (NCT01868477) | Novartis Pharmaceuticals | 2014-01-28 |
| Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan (NCT02042014) | Novartis Pharmaceuticals | 2014-01-22 |
| Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator. (NCT02017860) | Novartis Pharmaceuticals | 2014-01-16 |
| 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients (NCT02008916) | Novartis Pharmaceuticals | 2014-01-14 |
| Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma (NCT01870726) | Novartis Pharmaceuticals | 2014-01-09 |
| Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride (NCT02007278) | Novartis Pharmaceuticals | 2014-01-03 |
| A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection (NCT01836458) | Novartis Pharmaceuticals | 2014-01-01 |
| Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients (NCT02002702) | Novartis Pharmaceuticals | 2014-01-01 |
| Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles (NCT02015663) | Novartis Pharmaceuticals | 2014-01-01 |
| Effect of Hepatic Impairment on LDK378 Pharmacokinetics (NCT01950481) | Novartis Pharmaceuticals | 2014-01-01 |
| A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453 (NCT02052687) | Novartis Pharmaceuticals | 2014-01-01 |
| Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018) (NCT02014636) | Novartis Pharmaceuticals | 2013-12-27 |
| Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab (NCT02008890) | Novartis Pharmaceuticals | 2013-12-26 |
| A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients. (NCT02040584) | Novartis Pharmaceuticals | 2013-12-20 |
| A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis (NCT02038049) | Novartis Pharmaceuticals | 2013-12-20 |
| Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris (NCT01930175) | Novartis Pharmaceuticals | 2013-12-18 |
| Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD (NCT01948830) | Novartis Pharmaceuticals | 2013-12-17 |
| Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer (NCT01958021) | Novartis Pharmaceuticals | 2013-12-17 |
| A Phase 2 Study of BGJ398 in Patients With Recurrent GBM (NCT01975701) | Novartis Pharmaceuticals | 2013-12-09 |
| Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma (NCT01854606) | Novartis Pharmaceuticals | 2013-12-05 |
| Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) (NCT01950819) | Novartis Pharmaceuticals | 2013-12-03 |
| A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD (NCT01834885) | Novartis Pharmaceuticals | 2013-12-01 |
| Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients (NCT02002221) | Novartis Pharmaceuticals | 2013-12-01 |
| A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD (NCT01860066) | Novartis Pharmaceuticals | 2013-12-01 |
| ACZ885 for the Treatment of Abdominal Aortic Aneurysm (NCT02007252) | Novartis Pharmaceuticals | 2013-12-01 |
| Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) (NCT01976338) | Novartis Pharmaceuticals | 2013-11-12 |
| Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) (NCT01976312) | Novartis Pharmaceuticals | 2013-11-12 |
| Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma (NCT01912872) | Novartis Pharmaceuticals | 2013-11-11 |
| Extension in AS: Sustainability of Benefits, Safety and Tolerability (NCT01863732) | Novartis Pharmaceuticals | 2013-11-06 |
| A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics (NCT02005133) | Novartis Pharmaceuticals | 2013-11-01 |
| Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors (NCT01968915) | Novartis Pharmaceuticals | 2013-11-01 |
| Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma (NCT01959412) | Novartis Pharmaceuticals | 2013-11-01 |
| Urine Sample Collection From FOP Patients (NCT02066324) | Novartis Pharmaceuticals | 2013-11-01 |
| Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy (NCT01813019) | Novartis Pharmaceuticals | 2013-11-01 |
| Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients (NCT01922089) | Novartis Pharmaceuticals | 2013-11-01 |
| Study of FTY720 in Patients With Uveitis (NCT01791192) | Novartis Pharmaceuticals | 2013-11-01 |
| A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076. (NCT01972776) | Novartis Pharmaceuticals | 2013-11-01 |
| Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre) (NCT01972789) | Novartis Pharmaceuticals | 2013-10-31 |
| Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD (NCT01958918) | Novartis Pharmaceuticals | 2013-10-23 |
| Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (NCT01872260) | Novartis Pharmaceuticals | 2013-10-22 |
| A Rollover Study to Provide Continued Treatment With Eltrombopag (NCT01957176) | Novartis Pharmaceuticals | 2013-10-15 |
| Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants. (NCT01961609) | Novartis Pharmaceuticals | 2013-10-09 |
| Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF (NCT01870778) | Novartis Pharmaceuticals | 2013-10-02 |
| To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema (NCT01846299) | Novartis Pharmaceuticals | 2013-10-01 |
| Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy (NCT01852292) | Novartis Pharmaceuticals | 2013-10-01 |
| Phase 1b Trial of BGJ398/BYL719 in Solid Tumors (NCT01928459) | Novartis Pharmaceuticals | 2013-10-01 |
| Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo. (NCT01900782) | Novartis Pharmaceuticals | 2013-10-01 |
| A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension (NCT01870739) | Novartis Pharmaceuticals | 2013-10-01 |
| Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients (NCT01911325) | Novartis Pharmaceuticals | 2013-10-01 |